PATENT CLAIM ANALYSIS

Application Number: 16269744
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "210180"]

Abstract:
Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

Claim (Index 22):
The pharmaceutical composition according to  claim 21 , wherein the Btk-related disease is an allergic disease, an autoimmune disease, an inflammatory disease, a thromboembolic disease, or a cancer.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 99.0
- Lexical Diversity: 1.34615
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13700774', '15648941', '14564568', '15895036', '13833520']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8183061774088132
- 35 USC 102 Novelty (BERT): 0.541587577669492
- Combined Prediction Score: 0.7906343174348811
- Mean Citation Score: 383.247414
- Max Citation Score: 403.54996
- Similarity Product: 243.545483165555

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test